Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Affimed to Present Clinical and Preclinical Data on Immune Cell Engagers at ASH

Affimed N.V.
Posted on: 01 Nov 17

Heidelberg, Germany, November 1, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that the Company will present clinical and preclinical data on its immune cell engagers AFM13 and AFM26 at the 59 th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2017 in Atlanta, Georgia.

Poster Information

Title: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study (Abstract #1522)

Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I

Date: Saturday, December 9, 2017, 5:30 PM - 7:30 PM Eastern Time

Location: Hall A2 (Georgia World Congress Center)

Title: AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma (Abstract #3082)

Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II

Date: Sunday, December 10, 2017, 6:00 PM - 8:00 PM Eastern Time

Location: Hall A2 (Georgia World Congress Center)

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .

Contact:

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com , IR@affimed.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Affimed N.V. via GlobeNewswire
HUG#2145044
GlobeNewswire
globenewswire.com

Last updated on: 02/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.